2023 ESC Guidelines for the management of endocarditis
This guideline cites 3 of the 199 landmark trials in our Cardiology register.
- Issued by
- ESC
- Year
- 2023
- Source
- Delgado V, Ajmone Marsan N, et al. Eur Heart J. 2023;44(39):3948–4042.doi 10.1093/eurheartj/ehad193
The 2023 ESC endocarditis guideline formalises the Endocarditis Team, widens the role of multimodality imaging, opens the door to outpatient and partial oral antibiotic therapy, and abandons routine aminoglycoside combination therapy in native-valve staphylococcal disease. Randomised evidence in endocarditis is unusually thin — the three trials below are essentially all of it, and the guideline's remaining recommendations rest on cohorts and expert consensus.
Antibiotic therapy & oral step-down2
- 2019POETInfectious · IE · Oral step-down therapyIn 400 patients with stable left-sided endocarditis after ≥10 days of IV therapy, step-down to oral two-drug therapy was non-inferior to continued IV therapy for a composite of mortality, embolic events, relapse or unplanned cardiac surgery.9.0% vs 12.1%Read →
- 2006Fowler DaptomycinCardiology · Inflammatory · Antibiotic therapyIn 246 patients with Staphylococcus aureus bacteraemia with or without endocarditis, daptomycin was non-inferior to an antistaphylococcal penicillin or vancomycin plus initial low-dose gentamicin for treatment success 42 days after the end of therapy, with less renal toxicity.44.2% vs 41.7%Read →
Timing of valve surgery1
- 2012EASECardiology · Inflammatory · Surgical timingIn 76 patients with left-sided infective endocarditis, severe valve disease and large vegetations, early valve surgery within 48 hours reduced in-hospital death or embolic events at 6 weeks compared with conventional treatment with surgery only on clinical indication.HR 0.1095% CI 0.01-0.82Read →
Cited landmark trials not yet in the register4
Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.
- 2009Cosgrove (gentamicin toxicity)
Adjunctive low-dose gentamicin caused nephrotoxicity without clinical benefit — the reason routine aminoglycoside combination was dropped.
- 2009ICE-PCS
The international prospective cohort that redefined the modern epidemiology of endocarditis.
- 2019EURO-ENDO
ESC EORP registry — surgery was indicated but not performed in nearly a quarter of patients.
- 2022Thornhill (antibiotic prophylaxis)
Population data linking invasive dental procedures to endocarditis in high-risk patients.
Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.